Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By

48 Results

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 7/26/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 07/26/2021 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways, principal investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court

    Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Asst. Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Department of Psychiatry. He has presented or published in:

    Journal of Addictive Diseases (2015 and 2016), American Journal of Addiction (2013), Substance Abuse (2013), BridgeMI.com 2016-2018 (journalism co-op for setting policy), FoxNews.com (editorial) and CNN.com (news), Weekly medical columns in the Gladwin Record and Courier.

    MLive.com, NPR, Arizona Public Radio, American Public Radio and Michigan Public Radio, Adolescent Addiction from the Conrad Hilton Foundation, CORE REMS as a charter master faculty PCSS monthly training sponsored by SAMHSA/CSAT for 9 yr, MOA/MAOFP news letters; AOA publications & advocacy to recognize addiction medicine

    Dr. Morrone has published a naloxone book for families.  AMERICAN NARCAN (2017)  www.AmericanNarcan.com

    He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.

    Nationally and locally he has contributed numerous didactic pieces on opiates, cannabis dependence, primary care, NAS, state based medical marijuana, non-narcotic pain management to providers in recovery; to the state medical and national societies in this area. He is Deputy Medical Director to the Bay County Health Department and principal investigator on Bay County Heroin Task Force.

    He also holds a graduate degree in toxicology and pharmacology from the University of Missouri at Kansas City, graduate school of pharmacy. He also completed an MPH in Baltimore, MD.

    Most notable to pop culture cable TV news viewers is that he has been on Dr. Drew-HLN, CNN News Room, Nancy Grace-CNN Headline News, Court TV, CNN, Studio “B” FOXNews Channel and MSNBC giving medical opinions on drug addiction or death and the 6 stages of decomposition.  For international overdose awareness day (IOAD) he appeared on 23 TV stations in one day.

    Public service is no stranger to Dr. Morrone as he is a Deputy Chief Medical Examiner, a Diplomat of American College of Forensic Examiners and has been a volunteer firefighter. Dr. Morrone is an aggressive advocate for substance abuse treatment and overdose prevention at the FDA, HHS, SAMHSA and congress.  He also trained at the Armed Forces Institute of Pathology (AFIP) in Maryland.

    Spent 10 years as Medical Director at Hospice of Michigan, leaving hospice to do addiction full time. Dr. Morrone is a graduate of MSU, served his internship in internal medicine in Lansing at Ingham Regional Medical Center and his residency in family medicine at the Michigan State University statewide campus site at Bay Regional Medical Center. http://wwwAmericanNarcan.com.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 7/10/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 07/10/2021 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 6/28/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 06/28/2021 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways, principal investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court

    Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Asst. Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Department of Psychiatry. He has presented or published in:

    Journal of Addictive Diseases (2015 and 2016), American Journal of Addiction (2013), Substance Abuse (2013), BridgeMI.com 2016-2018 (journalism co-op for setting policy), FoxNews.com (editorial) and CNN.com (news), Weekly medical columns in the Gladwin Record and Courier.

    MLive.com, NPR, Arizona Public Radio, American Public Radio and Michigan Public Radio, Adolescent Addiction from the Conrad Hilton Foundation, CORE REMS as a charter master faculty PCSS monthly training sponsored by SAMHSA/CSAT for 9 yr, MOA/MAOFP news letters; AOA publications & advocacy to recognize addiction medicine

    Dr. Morrone has published a naloxone book for families.  AMERICAN NARCAN (2017)  www.AmericanNarcan.com

    He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.

    Nationally and locally he has contributed numerous didactic pieces on opiates, cannabis dependence, primary care, NAS, state based medical marijuana, non-narcotic pain management to providers in recovery; to the state medical and national societies in this area. He is Deputy Medical Director to the Bay County Health Department and principal investigator on Bay County Heroin Task Force.

    He also holds a graduate degree in toxicology and pharmacology from the University of Missouri at Kansas City, graduate school of pharmacy. He also completed an MPH in Baltimore, MD.

    Most notable to pop culture cable TV news viewers is that he has been on Dr. Drew-HLN, CNN News Room, Nancy Grace-CNN Headline News, Court TV, CNN, Studio “B” FOXNews Channel and MSNBC giving medical opinions on drug addiction or death and the 6 stages of decomposition.  For international overdose awareness day (IOAD) he appeared on 23 TV stations in one day.

    Public service is no stranger to Dr. Morrone as he is a Deputy Chief Medical Examiner, a Diplomat of American College of Forensic Examiners and has been a volunteer firefighter. Dr. Morrone is an aggressive advocate for substance abuse treatment and overdose prevention at the FDA, HHS, SAMHSA and congress.  He also trained at the Armed Forces Institute of Pathology (AFIP) in Maryland.

    Spent 10 years as Medical Director at Hospice of Michigan, leaving hospice to do addiction full time. Dr. Morrone is a graduate of MSU, served his internship in internal medicine in Lansing at Ingham Regional Medical Center and his residency in family medicine at the Michigan State University statewide campus site at Bay Regional Medical Center. http://wwwAmericanNarcan.com.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 6/19/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 06/19/2021 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 5/24/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 05/24/2021 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways, principal investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court

    Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Asst. Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Department of Psychiatry. He has presented or published in:

    Journal of Addictive Diseases (2015 and 2016), American Journal of Addiction (2013), Substance Abuse (2013), BridgeMI.com 2016-2018 (journalism co-op for setting policy), FoxNews.com (editorial) and CNN.com (news), Weekly medical columns in the Gladwin Record and Courier.

    MLive.com, NPR, Arizona Public Radio, American Public Radio and Michigan Public Radio, Adolescent Addiction from the Conrad Hilton Foundation, CORE REMS as a charter master faculty PCSS monthly training sponsored by SAMHSA/CSAT for 9 yr, MOA/MAOFP news letters; AOA publications & advocacy to recognize addiction medicine

    Dr. Morrone has published a naloxone book for families.  AMERICAN NARCAN (2017)  www.AmericanNarcan.com

    He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.

    Nationally and locally he has contributed numerous didactic pieces on opiates, cannabis dependence, primary care, NAS, state based medical marijuana, non-narcotic pain management to providers in recovery; to the state medical and national societies in this area. He is Deputy Medical Director to the Bay County Health Department and principal investigator on Bay County Heroin Task Force.

    He also holds a graduate degree in toxicology and pharmacology from the University of Missouri at Kansas City, graduate school of pharmacy. He also completed an MPH in Baltimore, MD.

    Most notable to pop culture cable TV news viewers is that he has been on Dr. Drew-HLN, CNN News Room, Nancy Grace-CNN Headline News, Court TV, CNN, Studio “B” FOXNews Channel and MSNBC giving medical opinions on drug addiction or death and the 6 stages of decomposition.  For international overdose awareness day (IOAD) he appeared on 23 TV stations in one day.

    Public service is no stranger to Dr. Morrone as he is a Deputy Chief Medical Examiner, a Diplomat of American College of Forensic Examiners and has been a volunteer firefighter. Dr. Morrone is an aggressive advocate for substance abuse treatment and overdose prevention at the FDA, HHS, SAMHSA and congress.  He also trained at the Armed Forces Institute of Pathology (AFIP) in Maryland.

    Spent 10 years as Medical Director at Hospice of Michigan, leaving hospice to do addiction full time. Dr. Morrone is a graduate of MSU, served his internship in internal medicine in Lansing at Ingham Regional Medical Center and his residency in family medicine at the Michigan State University statewide campus site at Bay Regional Medical Center. http://wwwAmericanNarcan.com.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 5/8/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 05/08/2021 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • Q&A Session: Group Based Opioid Treatment

    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 04/28/2021 at 6:00 PM (EDT)

    ORN Webinar Series: This is a follow up Q&A Session: Group Based Opioid Treatment webinar. The webinar "Group Based Opioid Treatment" introduced a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: This is a follow up Q&A Session: Group Based Opioid Treatment webinar. The webinar "Group Based Opioid Treatment"  introduced a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability.

    Goals & Objectives: 

    1. Identify the advantages of implementing a shared medical appointment for prescribing medication for OUD and incorporating group therapy.
    2. Recognize the impact the COVID pandemic has had on substance use disorders.
    3. Understand the benefits and challenges of utilizing telehealth to deliver group treatment.

    Needs Assessment: 

    There is a profound need to expand evidence based treatment for OUD in a manner that is efficient and effective. Providing a group based modality is an innovative way to meet this need. Doing so requires a sound understanding of the processes and particulars of group treatment rather than individual treatment. Furthermore, the COVID epidemic has created many challenges for people with substance use disorders and provision of treatment. An understanding of the unique dynamics of telemedicine delivery in a group format is a way to meet these challenges

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    James H. Berry, DO

    James H. Berry, DO, is an addiction psychiatrist and Chair of the Department of Behavioral Medicine and Psychiatry at West Virginia University School of Medicine. He and his colleagues at WVU have developed innovative community based treatment models in response to the addiction crisis in Appalachia and are actively engaged in novel neuromodulation research related to substance use disorders through WVU’s Rockefeller Neuroscience Institute. 

    Mary-Anne Kowol, MD, FASAM

    Mary-Anne Kowol, MD, FASAM - Guest Panelist
    Assistant Professor, Medical College of Wisconsin.

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 4/26/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 04/26/2021 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways, principal investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court

    Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Asst. Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Department of Psychiatry. He has presented or published in:

    Journal of Addictive Diseases (2015 and 2016), American Journal of Addiction (2013), Substance Abuse (2013), BridgeMI.com 2016-2018 (journalism co-op for setting policy), FoxNews.com (editorial) and CNN.com (news), Weekly medical columns in the Gladwin Record and Courier.

    MLive.com, NPR, Arizona Public Radio, American Public Radio and Michigan Public Radio, Adolescent Addiction from the Conrad Hilton Foundation, CORE REMS as a charter master faculty PCSS monthly training sponsored by SAMHSA/CSAT for 9 yr, MOA/MAOFP news letters; AOA publications & advocacy to recognize addiction medicine

    Dr. Morrone has published a naloxone book for families.  AMERICAN NARCAN (2017)  www.AmericanNarcan.com

    He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.

    Nationally and locally he has contributed numerous didactic pieces on opiates, cannabis dependence, primary care, NAS, state based medical marijuana, non-narcotic pain management to providers in recovery; to the state medical and national societies in this area. He is Deputy Medical Director to the Bay County Health Department and principal investigator on Bay County Heroin Task Force.

    He also holds a graduate degree in toxicology and pharmacology from the University of Missouri at Kansas City, graduate school of pharmacy. He also completed an MPH in Baltimore, MD.

    Most notable to pop culture cable TV news viewers is that he has been on Dr. Drew-HLN, CNN News Room, Nancy Grace-CNN Headline News, Court TV, CNN, Studio “B” FOXNews Channel and MSNBC giving medical opinions on drug addiction or death and the 6 stages of decomposition.  For international overdose awareness day (IOAD) he appeared on 23 TV stations in one day.

    Public service is no stranger to Dr. Morrone as he is a Deputy Chief Medical Examiner, a Diplomat of American College of Forensic Examiners and has been a volunteer firefighter. Dr. Morrone is an aggressive advocate for substance abuse treatment and overdose prevention at the FDA, HHS, SAMHSA and congress.  He also trained at the Armed Forces Institute of Pathology (AFIP) in Maryland.

    Spent 10 years as Medical Director at Hospice of Michigan, leaving hospice to do addiction full time. Dr. Morrone is a graduate of MSU, served his internship in internal medicine in Lansing at Ingham Regional Medical Center and his residency in family medicine at the Michigan State University statewide campus site at Bay Regional Medical Center. http://wwwAmericanNarcan.com.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • Group Based Opioid Treatment

    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 04/21/2021 at 6:00 PM (EDT)

    ORN Webinar Series: This webinar will introduce a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: This webinar will introduce a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability.

    Goals & Objectives: 

    1. Identify the advantages of implementing a shared medical appointment for prescribing medication for OUD and incorporating group therapy.
    2. Recognize the impact the COVID pandemic has had on substance use disorders.
    3. Understand the benefits and challenges of utilizing telehealth to deliver group treatment.

    Needs Assessment: 

     There is a profound need to expand evidence based treatment for OUD in a manner that is efficient and effective. Providing a group based modality is an innovative way to meet this need. Doing so requires a sound understanding of the processes and particulars of group treatment rather than individual treatment. Furthermore, the COVID epidemic has created many challenges for people with substance use disorders and provision of treatment. An understanding of the unique dynamics of telemedicine delivery in a group format is a way to meet these challenges

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    James H. Berry, DO

    James H. Berry, DO, is an addiction psychiatrist and Chair of the Department of Behavioral Medicine and Psychiatry at West Virginia University School of Medicine. He and his colleagues at WVU have developed innovative community based treatment models in response to the addiction crisis in Appalachia and are actively engaged in novel neuromodulation research related to substance use disorders through WVU’s Rockefeller Neuroscience Institute. 

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.

  • Q&A Session: Buprenorphine Induction for High Potency Synthetic Opioid Users

    Contains 3 Component(s), Includes Credits Recorded On: 04/14/2021

    ORN Webinar Series: Q&A Session following a presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO). This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: Q&A Session following a presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO)

    Goals & Objectives:

    At the conclusion of this activity participants should be able to:

    1. Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder
    2. Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
    3. Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl 

     Needs Assessment: 

    HPSO are the leading cause of overdose death in the US and minimal empiric data exist to guide treatment decisions. Attendees will be gain understanding of the pharmacology of HPSO, understand how current OUD pharmacotherapy interacts with HPSOs, and potential treatment options including long-acting injectable buprenorphine.

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    John J. Mariani, MD

    Dr. John Mariani is an Associate Professor of Clinical Psychiatry at the Columbia University Irving Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute. Dr. Mariani is the Director of the Substance Treatment and Research Service (STARS) of Columbia University Irving Medical Center, which is a facility for conducting substance use disorder pharmacotherapy research. Dr. Mariani maintains a busy private practice in Manhattan and is the Medical Advisor to the Major League Baseball Players Association.

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.